Show Notes
UK, Zoe symptom studyUploaded 03-09-22https://health-study.joinzoe.com/dataDaily new cases = 106,548Current symptomatic prevalence = 1,488,559UK official datahttps://coronavirus.data.gov.ukPatients admitted, 4,124 down 14% (past 7 days)With covid or for covid?Deaths, 419, down 38% (past 7 days)ONS latesthttps://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19/latestinsightsW/E 23rd August, prevalence1.64% in England (1 in 60 people)1.56% in Wales (1 in 65 people) 1.95% in Northern Ireland (1 in 50 people) 1.82% in Scotland (1 in 55 people)Reinfections within the omicron wave14.6%Alpha, 1.8%Delta, 1%Risk of BA.5 Infection among Persons Exposed to Previous SARS-CoV-2 Variantshttps://www.nejm.org/doi/full/10.1056/NEJMc2209479?query=TOC&cid=NEJM%20eToc,%20September%201,%202022%20DM1402792_NEJM_Non_Subscriber&bid=1141953912https://www.nejm.org/doi/suppl/10.1056/NEJMc2209479/suppl_file/nejmc2209479_appendix.pdfWuhan-Hu-1 55.7%Alpha 58.8%Delta 64.5%BA.1 / BA.2 76.8% (UK, 84.4%)Long covid2.0 million people in private households in the UK (3.1%)Of those83% symptoms at least 12 weeks45% at least one year22% at least two yearsSymptomsFatigue, 62%Shortness of breath, 37%Difficulty concentrating, 33%Muscle ache, 31%Symptoms adversely affected the day-to-day activities1.5 million people, (73% of those with SRLC)China, millions in Covid lockdownhttps://www.theguardian.com/world/2022/aug/31/china-places-millions-into-covid-lockdown-again-as-economy-continues-to-struggleChina, cases, + 1,717 cases, majority asymptomaticSporadic cases around ChinaSouthern cities of Shenzhen and GuangzhouNorthern port city of DalianWestern metropolis of Chengdu to ShijiazhuangCentral Hebei provinceVarying levels of restrictions, closure of venues and restaurantsDelayed school reopeningForeign visitors, more than a week of quarantine hotels, sanitary conditions often poorMasking and regular testing, close contacts forcibly transported to field hospitalsWorld Health Organization, China’s policy unsustainableAnbound Research CenterPresident Xi Jinping’s government, Preventing the risk of economic stall should be the priority taskModerna sues Pfizer and BioNTech https://www.washingtonpost.com/business/2022/08/26/moderna-pfizer-covid-lawsuit/?utm_campaign=wp_to_your_health&utm_medium=email&utm_source=newsletter&wpisrc=nl_tyhhttps://www.documentcloud.org/documents/22266043-moderna-complaint?responsive=1&title=1MODERNA SUES PFIZER AND BIONTECH FOR INFRINGING PATENTS CENTRAL TO MODERNA'S INNOVATIVE MRNA TECHNOLOGY PLATFORMAUGUST, 26, 2022https://investors.modernatx.com/news/news-details/2022/Moderna-Sues-Pfizer-and-BioNTech-for-Infringing-Patents-Central-to-Modernas-Innovative-mRNA-Technology-Platform/default.aspxModerna Chief Legal Officer Shannon Thyme KlingerWe believe that Pfizer and BioNTech unlawfully copied Moderna’s inventions, and they have continued to use them without permissionPfizerWe are surprised by the litigation given the Pfizer/BioNTech COVID-19 vaccine was based on BioNTech’s proprietary mRNA technology and developed by both BioNTech and Pfizer Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices
More from Dr. John Campbell
Protectors from hospitalisation, the story so far.Oral meds than can be prescribed from home with onset of symptomsUploaded 07-11-21Molnupiravir, approved by MHRAhttps://www.gov.uk/government/news/first-oral-antiviral-for-covid-19-lagevrio-molnupiravir-approved-by-mhraThe antiviral was found to be safe and effective following a stringent review of the available evidence.https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/Public domain data, Merck press release$ 700 per 5-day courseUnder 50% reduction in deuteriationEffect of early treatment with fluvoxamineTogether Trial groupPublic domain data, Peer reviewed trial in the Lancethttps://clinicaltrials.gov/ct2/show/NCT04727424https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(21)00448-4/fulltextAdults with a risk factor$4 for a 10-day course32% protection against hospitalization32% protection against deathFluvoxamine is approved by the Food and Drug Administration as an antidepressantDoctors already can prescribe it off-label — using their clinical judgmenthttps://www.washingtonpost.com/science/2021/10/28/antidepressant-fluvoxamine-coronavirus-lancet/?https://bnf.nice.org.uk/drug/fluvoxamine-maleate.htmlhttps://www.togethertrial.comIvermectin, Together trial results not yet releasedPFIZER’S NOVEL COVID-19 ORAL ANTIVIRAL TREATMENT CANDIDATE REDUCED RISK OF HOSPITALIZATION OR DEATH BY 89% IN INTERIM ANALYSIS OF PHASE 2/3 EPIC-HR STUDYhttps://www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidatePublic domain data, Pfizer press releasePAXLOVID™ (PF-07321332; ritonavir)Found to reduce the risk of hospitalization or death by 89% Compared to placebo in non-hospitalized high-risk adults with COVID-19Through Day 28PAXLOVID groupNo deathsPlacebo group10 deathsPfizer plans to submit the data as part of its ongoing rolling submission to the U.S. FDA for Emergency Use Authorization (EUA) as soon as possiblePhase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) Randomized, double-blind study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness Scheduled interim analysis89% reduction in risk of COVID-19-related hospitalization or death from any cause compared to placeboIn patients treated within 3 days of symptom onsetPAXLOVID group0.8% of patients hospitalized3/389 hospitalized with no deathsPlacebo group7.0% of patients hospitalized or died27/385 hospitalizedwith 7 subsequent deaths(p less than 0.0001) 1 in 10,000 chanceIn patients treated within 5 days of symptom onsetPAXLOVID group1.0% of patients hospitalized6/607 hospitalized with no deathsPlacebo group6. 7% of patients hospitalized or died41/612 hospitalized,with 10 subsequent deathsp less than 0.0001At the recommendation of an independent Data Monitoring Committee and in consultation with the U.S. Food and Drug Administration (FDA), Pfizer will cease further enrollment into the studydue to the overwhelming efficacy demonstrated in these resultsAbout the Phase 2/3 EPIC-HR Study Interim Analysis1,219 adults enrolled out of 3,000 plannedNorth and South America, Europe, Africa, and AsiaEnrolled individuals had a laboratory-confirmed diagnosis of SARS-CoV-2 infectionMild to moderate symptomsAt least one characteristic or underlying medical conditionRandomized (1:1) to receive PAXLOVID™ or placebo orally every 12 hours for five daysAbout the Phase 2/3 EPIC-HR Study Safety DataSafety data, n = 1881Treatment-emergent adverse eventsPAXLOVID™group 19%Placebo group21%Most of which Learn more about your ad choices. Visit megaphone.fm/adchoices
Professor Angus Dalgleish, physician, oncologist, pathologist, medical researcher and author. Get your copy of The Death of Science, https://gazellebookservices.co.uk/pro...Uploaded 06-01-24Also by Professor Dalgleish, The Origin of the Virus: The hidden truths behind the microbe that killed millions of people, https://www.amazon.co.uk/dp/185457106... Learn more about your ad choices. Visit megaphone.fm/adchoices Learn more about your ad choices. Visit megaphone.fm/adchoices